Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$9.4MCash on Hand
22.9mo Cash Runway
Follow TTRX by emailGet an email when TTRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TTRX, unsubscribe in one click. Privacy
📣 What TTRX Says Is Next
Q2 2027 · “Subject to successful completion of each phase and capital availability. 4. https://www.mdedge.com/dermatology/article/99462/hair - nails/onychomycosis - treatment - united - states 21 Planned Phase 3 Pivotal Trial Q4 2028 Topline Results Expected Q2 2027 First Patient Dosing Planned 1H 2028 Interim Analysis Expected o Mycological Cure at Week 52 o < 5% Clinical Involvement at Week 52 o < 5% Mycological Involvement at Week 52 Population:”
Company press release, Nov 10, 2026 · SEC filing
first quarter of 2027 · “With HS enrollment beginning and our Phase 2b atopic dermatitis trial moving forward, we expect the first quarter of 2027 to be a very active time for Turn.”
Company press release, Nov 9, 2026 · SEC filing
first quarter of 2027 · GX-03: ““Our Phase 2b trial is designed to find out whether those results can be repeated in a larger group of patients.” Turn Therapeutics accelerates Phase 2a trial of GX-03 in hidradenitis suppurativa We are also accelerating patient enrollment in the planned Phase 2a trial of GX-03 for hidradenitis suppurativa (HS) which is now expected to begin in the first quarter of 2027, ahead of the previously announced second-quarter target.”
Company press release, Nov 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Financing Registers resale of up to 25,362,950 shares by selling stockholders, including GEM entities holding up to 6,621,190 shares. The company receives no proceeds. Under a purchase agreement, the company may sell up to $85 million of stock to GEM at its discretion. Shares closed at $9.48 on Nov 6, 2026. Form 424B3 · SEC filing
Nov 16, 2026 ·
Financing Turn Therapeutics filed a prospectus for an at-the-market offering of up to $50,000,000 of common stock through TD Cowen as sales agent, with commissions of up to 3.0% of gross proceeds. Nasdaq closing price was $9.48 on November 6, 2026. Form 424B5 · SEC filing
Nov 10, 2026 ·
Clinical trial Turn Therapeutics released an updated November 2026 investor presentation, furnished as Exhibit 99.1. It reports Phase 2 AD data showing 59.3% vs 40.7% week 4 vIGA success, and says Phase 2 topline results are expected Q1 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Clinical trial Reported Q3 2026 results and updates: full Stage 1 atopic dermatitis population showed 59.3% clear or almost clear skin at Week 4 versus 30.4% on vehicle. HS Phase 2a now expected to begin Q1 2027. Cash, with $10.4 million at September 30, funds operations into Q3 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 9, 2026 ·
Financing Turn Therapeutics filed a resale registration covering up to 25,362,950 shares for selling stockholders, including 6,621,190 shares for GEM under a committed equity facility with an $85,000,000 aggregate limit. The company will not receive proceeds from these sales. Form S-3 · SEC filing
Nov 9, 2026 ·
Financing Turn Therapeutics filed a shelf registration for up to $150,000,000 in securities, including a $50,000,000 common stock sales agreement with TD Securities (USA) LLC dated November 9, 2026. Offering amounts and prices will be set in later prospectus supplements. Form S-3 · SEC filing
Oct 7, 2026 ·
Turn Therapeutics released an updated October 2026 investor presentation, furnished as Exhibit 99.1. It reiterates that GX-03 Phase 2 topline results for moderate to severe atopic dermatitis are expected Q1 2027, with an FDA Type B meeting planned for Q4 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · Phase 2/3 · Recruiting · A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not TTRX's own candidates): Petrolatum Ointment.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TTRX holds $9.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.2M/quarter from operations,
an estimated runway of 22.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:48 · Elevated
Cash runway 23 months +8
ATM program on file since Nov 2026 +15
Shelf registration (S-3, Nov 2026) +10
Going-concern doubt in the latest 10-Q +15Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that these condensed consolidated financial statements as of September 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.10-Q, Nov 2026
Share count 30,572,704 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TTRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TTRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.